{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:34:52Z","timestamp":1790094892267,"version":"4.0.1"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"07\/08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Seit Anfang der 1990er Jahre ist bekannt, dass das Neuropeptid Calcitonin\n                    Gene-Related Peptid (CGRP) eine Schl\u00fcsselrolle in der Pathophysiologie der\n                    Migr\u00e4ne spielt. Mit dieser Entdeckung ergaben sich in der Migr\u00e4netherapie neue\n                    Angriffspunkte f\u00fcr Medikamente, die in den letzten Jahren unser therapeutisches\n                    Arsenal revolutioniert haben. W\u00e4hrend bisherige Prophylaktika relativ\n                    unspezifisch wirkten und mit oft nicht tolerablen Nebenwirkungen einhergingen,\n                    entstanden mit CGRP als Zielstruktur in der Migr\u00e4neprophylaxe gut vertr\u00e4gliche\n                    und hocheffektive neue Therapieoptionen. Die zwei Hauptklassen der\n                    CGRP-spezifischen Migr\u00e4netherapie sind monoklonale Antik\u00f6rper, die CGRP oder den\n                    CGRP-Rezeptor binden und Gepante, CGRP-Rezeptor Antagonisten, die aufgrund ihrer\n                    molekularen Eigenschaften die intrazellul\u00e4re Signaltransmission blockieren. In\n                    gro\u00dfen Zulassungsstudien konnte die Sicherheit, Vertr\u00e4glichkeit und Wirksamkeit\n                    von monoklonalen CGRP-Antik\u00f6rpern in der prophylaktischen Therapie der\n                    episodischen und chronischen Migr\u00e4ne nachgewiesen werden. Gleiches gilt f\u00fcr den\n                    Einsatz verschiedener Gepante, die sich in der Akuttherapie als Alternative zu\n                    Triptanen und bei kontinuierlicher Einnahme als Prophylaktika in klinischen\n                    Studien als effektiv und sicher herausstellten. In dieser \u00dcbersichtsarbeit\n                    m\u00f6chten wir den aktuellen Stand der Forschung zur CGRP-spezifischen\n                    Migr\u00e4netherapie und Erkenntnisse aus ersten Anwendungsdaten darlegen.<\/jats:p>","DOI":"10.1055\/a-2276-2239","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T23:50:04Z","timestamp":1711669804000},"page":"277-282","source":"Crossref","is-referenced-by-count":2,"title":["Anti-CGRP basierte Migr\u00e4nemedikamente \u2013 eine \u00dcbersicht der\n                    Studienlage"],"prefix":"10.1055","volume":"92","author":[{"given":"Paul","family":"Triller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Charit\u00e9 Universit\u00e4tsmedizin\n                    Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Charit\u00e9 Universit\u00e4tsmedizin\n                    Berlin, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9, Berlin,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"M Ashina","year":"2020","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656","article-title":"New Generation Gepants: Migraine Acute and Preventive Medications","volume":"11","author":"D Moreno-Ajona","year":"2022","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for\n                    Migraine","volume":"381","author":"R B Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet\n                    for the acute treatment of migraine: a randomised, phase 3, double-blind,\n                    placebo-controlled trial","volume":"394","author":"R Croop","year":"2019","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised,\n                    double-blind, placebo-controlled trial","volume":"397","author":"R Croop","year":"2021","journal-title":"The Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the Treatment of Migraine","volume":"381","author":"D W Dodick","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated\n                    Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical\n                    Trial","volume":"322","author":"R B Lipton","year":"2019","journal-title":"Jama"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the\n                    prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3\n                    trial","volume":"19","author":"P J Goadsby","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","article-title":"Time course of efficacy of atogepant for the preventive treatment of migraine:\n                    Results from the randomized, double-blind ADVANCE trial","volume":"42","author":"T J Schwedt","year":"2022","journal-title":"Cephalalgia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a\n                    randomised, double-blind, placebo-controlled, phase 3 trial","author":"P Pozo-Rosich","year":"2023","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: A Phase 2\/3\n                    double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"R Croop","year":"2022","journal-title":"Headache"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A Controlled Trial of Erenumab for Episodic Migraine","volume":"377","author":"P J Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"D W Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a\n                    randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"S Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/s0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom\n                    two-to-four previous preventive treatments were unsuccessful: a randomised,\n                    double-blind, placebo-controlled, phase 3b study","volume":"392","author":"U Reuter","year":"2018","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2724","DOI":"10.1212\/wnl.0000000000012029","article-title":"Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY\n                    Study","volume":"96","author":"P J Goadsby","year":"2021","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine \u2013 a randomised,\n                    double-blind, active-controlled phase 4 trial","volume":"42","author":"U Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab Compared With Placebo for Prevention of Episodic\n                    Migraine: A Randomized Clinical Trial","volume":"319","author":"D W Dodick","year":"2018","journal-title":"Jama"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"S D Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/s0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented\n                    failure to up to four migraine preventive medication classes (FOCUS): a\n                    randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"M D Ferrari","year":"2019","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1\n                    Randomized Clinical Trial","volume":"75","author":"V L Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine:\n                    Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"V Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/wnl.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind,\n                    placebo-controlled REGAIN study","volume":"91","author":"H C Detke","year":"2018","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/s1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine\n                    preventive medication from two to four categories had failed (CONQUER): a\n                    multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"W M Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled\n                    study (PROMISE-1)","volume":"40","author":"M Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/wnl.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine:\n                    PROMISE-2","volume":"94","author":"R B Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/s1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with\n                    two-to-four previous preventive treatment failures (DELIVER): a multi-arm,\n                    randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"M Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral\n                    Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational\n                    Study","volume":"11","author":"B Raffaelli","year":"2020","journal-title":"Front Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/wnl.0000000000201008","article-title":"Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP\n                    (Receptor) Antibodies: A Prospective Follow-up Study","volume":"99","author":"S de Vries Lentsch","year":"2022","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis:\n                    a prospective, longitudinal cohort study","volume":"42","author":"B Raffaelli","year":"2022","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","article-title":"Effect of switching to erenumab in non-responders to a CGRP ligand antibody\n                    treatment in migraine: A real-world cohort study","volume":"14","author":"L H Overeem","year":"2023","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070934","article-title":"A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies:\n                    Predicting Response","volume":"16","author":"J B Hong","year":"2023","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2276-2239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:08:56Z","timestamp":1730815736000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2276-2239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":32,"journal-issue":{"issue":"07\/08","published-online":{"date-parts":[[2024,7,18]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2276-2239","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}